Although soluble LFA-3 levels are higher in patients with liver cirrhosis and hepatocellular carcinomas [38, 47] than in healthy donors, they remain globally similar to what has been measured for hematological malignancies [38], including our 41 CLL patients. This evidence concerns the gene CD58 and B-cell chronic lymphocytic leukemia.